PRQR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders...

Stats
Dagens volum	228 504
Gjennomsnittsvolum	204 070
Markedsverdi	161.63M
EPS	€0 ( 2024-04-03 )
Neste inntjeningsdato	( €-0.120 ) 2024-05-21
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.41
ATR14	€0.0150 (0.75%)

Volum Korrelasjon

Lang: 0.14 (neutral)

Kort: 0.74 (moderate)

Signal:(53.792) Neutral

ProQR Therapeutics NV Korrelasjon

10 Mest positive korrelasjoner
ECHO	0.961
SIOX	0.958
MLVF	0.954
IIN	0.95
CDZI	0.949
EXAS	0.942
BTWN	0.94
EXFO	0.934
GDNR	0.933
BKCH	0.932

10 Mest negative korrelasjoner
SNPX	-0.971
UTME	-0.963
ISPO	-0.956
PDBC	-0.95
LARK	-0.944
KTTA	-0.943
RIVN	-0.937
OP	-0.936
HMNF	-0.934
PIII	-0.934

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ProQR Therapeutics NV Korrelasjon - Valuta/Råvare

0.70
( moderate )

0.68
( moderate )

0.00
( neutral )

-0.18
( neutral )

ProQR Therapeutics NV Økonomi

Annual	2023
Omsetning:	€6.38M
Bruttogevinst:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2023
Omsetning:	€6.38M
Bruttogevinst:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2022
Omsetning:	€4.04M
Bruttogevinst:	€1.56M (38.68 %)
EPS:	€-0.910

FY	2021
Omsetning:	€1.35M
Bruttogevinst:	€0.00 (0.00 %)
EPS:	€-1.231

Financial Reports:

No articles found.

ProQR Therapeutics NV

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.